Key moment for Lundbeck with schizophrenia drug launch

21 December 2018

The first quarter of 2019 will be an important one for Lundbeck (LUND: CO) as it moves on from the failure of its DAYBREAK trial of a schizophrenia drug with the launch of another medicine for the condition.

Lundbeck has given brexiprazole the brand name Rexulti in Switzerland, where it will launch on January 1, and Rxulti in European Union countries, where the drug will be made available through the course of 2019 and 2020.

This medicine was approved by the European Commission in July for the treatment of schizophrenia in adults. The once-daily second generation oral antipsychotic was discovered by Japanese drugmaker Otsuka (TYO: 4578), which is co-developing it alongside the Danish CNS specialist.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK